Identification of high-risk coronary heart disease patients receiving atypical antipsychotics: Single low-density lipoprotein cholesterol threshold or complex national standard?

Journal of Clinical Psychiatry

Volumn 69, Issue 4, 2008, Pages 578-583

  Correll, Christoph U ^a   Kane, John M ^b   Manu, Peter ^b  

^a ZUCKER HILLSIDE HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANXIOLYTIC AGENT; ARIPIPRAZOLE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HIGH RISK PATIENT; HUMAN; ISCHEMIC HEART DISEASE; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; PATIENT ASSESSMENT; PRIORITY JOURNAL; RISK FACTOR;

EID: 44849113965     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v69n0409     Document Type: Article

References (27)

1. Osby U, Correia N, Brandt L, et al. Time trends in schizophrenia mortality in Stockholm County, Sweden: cohort study. BMJ 2000 Aug;321(7259):483-484
2. Enger C, Weatherby L, Reynolds RF, et al. Serious cardiovascular events and mortality among patients with schizophrenia. J Nerv Ment Dis 2004;192:19-27
3. Colton CW, Manderscheid RW. Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states. Prev Chronic Dis 2006 Apr;3(2):A42
4. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005;19(suppl 1):1-93
5. Meyer J, Koro CE, L'Italien GJ. The metabolic syndrome and schizophrenia: a review. Int Rev Psychiatry 2005 Jun;17(3):173-180
6. Correll CU. Balancing efficacy and safety in treatment with antipsychotics. CNS Spectr 2007;12(10 suppl 17):12-20,35
7. De Hert M, van Winkel R, Van Eyck D, et al. Prevalence of diabetes, metabolic syndrome and metabolic abnormalities in schizophrenia over the course of the illness: a cross-sectional study. Clin Pract Epidemol Ment Health 2006 Jun;2:14
8. Osborn DP, Levy G, Nazareth I, et al. Relative risk of cardiovascular and cancer mortality in people with severe mental illness from the United Kingdom's General Practice Research Database. Arch Gen Psychiatry 2007 Feb;64(2):242-249. Erratum in: Arch Gen Psychiatry 2007 Jun;64(6):736
9. Henderson DC, Nguyen DD, Copeland PM, et al. Clozapine, diabetes mellitus, hyperlipidemia, and cardiovascular risks and mortality: results of a 10-year naturalistic study. J Clin Psychiatry 2005 Sep;66(9):1116-1121
10. Cohn T, Prud'homme D, Streiner D, et al. Characterizing coronary heart disease risk in chronic schizophrenia: high prevalence of the metabolic syndrome. Can J Psychiatry 2004;49:753-760
11. Goff DC, Sullivan LM, McEvoy JP, et al. A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. Schizophr Res 2005 Dec;80(1):45-53
12. Correll CU, Frederickson AM, Kane JM, et al. Metabolic syndrome and the risk of coronary heart disease in 367 patients treated with secondgeneration antipsychotic drugs. J Clin Psychiatry 2006 Apr;67(4):575-583
13. Buckley PF, Miller DD, Singer B, et al. Clinicians' recognition of the metabolic adverse effects of antipsychotic medications. Schizophr Res 2005 Nov;79(2-3):281-288
14. Newcomer JW, Nasrallah HA, Loebel AD. The Atypical Antipsychotic Therapy and Metabolic Issues National Survey: practice patterns and knowledge of psychiatrists. J Clin Psychopharmacol 2004 Oct;24(5 suppl 1):S1-S6
15. Weissman EM, Zhu CW, Schooler NR, et al. Lipid monitoring in patients with schizophrenia prescribed second-generation antipsychotics. J Clin Psychiatry 2006 Sep;67(9):1323-1326
16. Nasrallah HA, Meyer JM, Goff DC, et al. Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline. Schizophr Res 2006 Sep;86(1-3):15-22
17. Correll CU, Harris JL, Pantaleon Moya RA, et al. Low-density lipoprotein cholesterol in patients treated with atypical antipsychotics: missed targets and lost opportunities. Schizophr Res 2007;92:103-107
18. Cohn TA, Sernyak MJ. Metabolic monitoring for patients treated with antipsychotic medications. Can J Psychiatry 2006 Jul;51(8):492-501
19. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285(19):2486-2497
20. Hennekens CH, Hollar D, Eidelman RS, et al. Update for primary healthcare providers: recent statin trials and revised National Cholesterol Education Program III guidelines. MedGenMed 2006 Feb;8(1):54
21. Grundy SM, Cleeman JI, Merz CN, et al. Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol 2004;44(3):720-732
22. Marder SR, Essock SM, Miller AL, et al. Physical health monitoring of patients with schizophrenia. Am J Psychiatry 2004 Aug;161(8):1334-1349
23. Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. The Expert Panel. Arch Intern Med 1988 Jan;148(1):36-69
24. Wilson PW, D'Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation 1998;97:1837-1847
25. Frayne SM, Halanych JH, Miller DR, et al. Disparities in diabetes care: impact of mental illness. Arch Intern Med 2005;165(22):2631-2638
26. Druss BG, Bradford WD, Rosenheck RA, et al. Quality of medical care and excess mortality in older patients with mental disorders. Arch Gen Psychiatry 2001;58:565-572
27. Foy R, Eccles MP, Jamtvedt G, et al. What do we know about how to do audit and feedback? pitfalls in applying evidence from a systematic review. BMC Health Serv Res 2005 Jul;5:50